Next Article in Journal
Spatial and Pregnancy-Related Changes in the Protein, Amino Acid, and Carbohydrate Composition of Bovine Oviduct Fluid
Next Article in Special Issue
Role of Somatostatin in the Regulation of Central and Peripheral Factors of Satiety and Obesity
Previous Article in Journal
Genome-Wide Identification of Metal Tolerance Protein Genes in Populus trichocarpa and Their Roles in Response to Various Heavy Metal Stresses
Previous Article in Special Issue
Novel Drug-Like Somatostatin Receptor 4 Agonists are Potential Analgesics for Neuropathic Pain
Review

Somatostatin Analogs in Clinical Practice: A Review

1
Department of Endocrinology, “La Paz” University Hospital. Paseo de la Castellana, 261, 28046 Madrid, Spain
2
Department of Endocrinology, “Fundación Jiménez-Diaz” University Hospital. Av. de los Reyes Católicos, 2, 28040 Madrid, Spain
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(5), 1682; https://doi.org/10.3390/ijms21051682
Received: 31 December 2019 / Revised: 22 February 2020 / Accepted: 25 February 2020 / Published: 29 February 2020
(This article belongs to the Special Issue Somatostatin)
Somatostatin analogs are an invaluable therapeutic option in the diagnosis and treatment of somatotropinomas, thyrotropinomas, and functioning and non-functioning gastroenteropancreatic neuroendocrine tumors. They should also be considered an effective and safe therapeutic alternative to corticotropinomas, gonadotropinomas, and prolactinomas resistant to dopamine agonists. Somatostatin analogs have also shown to be useful in the treatment of other endocrine diseases (congenital hyperinsulinism, Graves’ orbitopathy, diabetic retinopathy, diabetic macular edema), non-endocrine tumors (breast, colon, prostate, lung, and hepatocellular), and digestive diseases (chronic refractory diarrhea, hepatorenal polycystosis, gastrointestinal hemorrhage, dumping syndrome, and intestinal fistula). View Full-Text
Keywords: Somatostatin analog; pituitary adenoma; neuroendocrine tumor; cancer; carcinoid; lanreotide; octreotide; pasireotide Somatostatin analog; pituitary adenoma; neuroendocrine tumor; cancer; carcinoid; lanreotide; octreotide; pasireotide
Show Figures

Figure 1

MDPI and ACS Style

Gomes-Porras, M.; Cárdenas-Salas, J.; Álvarez-Escolá, C. Somatostatin Analogs in Clinical Practice: A Review. Int. J. Mol. Sci. 2020, 21, 1682. https://doi.org/10.3390/ijms21051682

AMA Style

Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin Analogs in Clinical Practice: A Review. International Journal of Molecular Sciences. 2020; 21(5):1682. https://doi.org/10.3390/ijms21051682

Chicago/Turabian Style

Gomes-Porras, Mariana, Jersy Cárdenas-Salas, and Cristina Álvarez-Escolá. 2020. "Somatostatin Analogs in Clinical Practice: A Review" International Journal of Molecular Sciences 21, no. 5: 1682. https://doi.org/10.3390/ijms21051682

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop